Dr Tom York, Richmond Pharmacology’s Associate Medical Director, recently wrote for Pharmaceutical Market Europe where he outlined how telemonitoring can support the patient to manage chronic diseases through a flexible treatment environment, as well as increase productivity in the pharmaceutical industry.

Richmond Pharmacology always searches for the most innovative processes to improve clinical trials and the patients’ experiences and treatments. Clinicians can review data provided by patients in real time, allowing them to quickly intervene to adjust therapy. For example, remote monitoring can help speed diagnosis and improve treatment outcomes in trials for ATTR cardiac amyloidosis (ATTR-CM). Furthermore, telemonitoring has many benefits, including savings to clinical trial management and providing the path for the development of new models of clinical trials, such as decentralised clinical trials.

CROs, such as Richmond Pharmacology, are transforming the way trials are delivered and data is analysed. Telemonitoring can be utilised in advancing models of clinical trials, all while saving substantial time and resources for sponsors, facilitating faster progress to phase III studies, and ensuring, over time, that approved medicines are reaching the patients who need them. However, Telemonitoring does not just represent a change in process, it requires different skills, new ways of working, and training programmes that keep pharmaceutical doctors aligned with the latest practices and trends. 

To read the full article, click here.

Latest news

Futureproofing early phase clinical research for the next generation of investigators.

March 20, 2023
Richmond Pharmacology’s experienced Principal investigators and Co-investigators recently gave expert feedback on the ICH M11 (CeSHarP) protocol template.
Read more

Director of Operations, Keith Berelowitz, has been appointed as the Research Ethics Committee Chair for the Health Research Authority.

January 19, 2023
Keith Berelowitz will be responsible for ensuring that all ethical possibilities are explored in relation to new research.
Read more


13th International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clinical Investigation of Drug-Drug Interactions

Sunday, June 4th to Tuesday June 6th 2023
Exchange research-based knowledge on drug-drug interactions (DDIs) among all interested stakeholders from pharmaceutical industry, regulatory authorities, academic and health care delivery backgrounds and perspectives.
View event